Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals logo
$1.30 -0.02 (-1.52%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.21 -0.09 (-6.92%)
As of 03/28/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Key Stats

Today's Range
$1.21
$1.38
50-Day Range
$1.30
$7.13
52-Week Range
$1.21
$965.00
Volume
161,488 shs
Average Volume
276,800 shs
Market Capitalization
$1.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Buy

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Remove Ads

CNS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

CNSP MarketRank™: 

CNS Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CNS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about CNS Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CNS Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CNS Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about CNS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.17% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 32.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CNS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CNS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.17% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently decreased by 32.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CNS Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 13 people have searched for CNSP on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

  • Read more about CNS Pharmaceuticals' insider trading history.
Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNSP Stock News Headlines

CNS Pharmaceuticals' (CNSP) Hold Rating Reaffirmed at Maxim Group
CNS Pharmaceuticals announces primary analysis of berubicin in GBM
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
See More Headlines

CNSP Stock Analysis - Frequently Asked Questions

CNS Pharmaceuticals' stock was trading at $6.02 at the beginning of 2025. Since then, CNSP shares have decreased by 78.4% and is now trading at $1.30.
View the best growth stocks for 2025 here
.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced its earnings results on Tuesday, November, 14th. The company reported ($2,700.00) EPS for the quarter, beating analysts' consensus estimates of ($4,325.00) by $1,625.00.

CNS Pharmaceuticals's stock reverse split before market open on Friday, February 21st 2025. The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

Top institutional shareholders of CNS Pharmaceuticals include Jane Street Group LLC (0.73%), Geode Capital Management LLC (0.67%), Citadel Advisors LLC (0.56%) and XTX Topco Ltd (0.51%). Insiders that own company stock include Waldemar Priebe, John M Climaco, Christopher Downs and Jerzy Gumulka.
View institutional ownership trends
.

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and General Electric (GE).

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNSP
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+1,823.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($35.66) per share
Price / Book
-0.04

Miscellaneous

Free Float
57,447,000
Market Cap
$1.50 million
Optionable
Not Optionable
Beta
2.65
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CNSP) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners